Scarica l'app Stockscreener
42.13
1.20%
0.50
Dopo l'orario di chiusura:
42.13
Precedente Chiudi:
$41.63
Aprire:
$41.64
Volume 24 ore:
520.15K
Relative Volume:
0.79
Capitalizzazione di mercato:
$1.81B
Reddito:
$4.85M
Utile/perdita netta:
$-114.75M
Rapporto P/E:
-12.96
EPS:
-3.25
Flusso di cassa netto:
$-100.36M
1 W Prestazione:
-4.81%
1M Prestazione:
+8.81%
6M Prestazione:
+118.40%
1 anno Prestazione:
+79.28%
Intervallo 1D:
$40.98
$43.19
Intervallo di 1 settimana:
$40.98
$44.60
Portata 52W:
$13.37
$45.45
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
42.13 | 1.78B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Bain Capital Life Sciences Investors LLC Has $46.24 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
What drives Dianthus Therapeutics Inc 87E stock priceLow Risk Investment Ideas & Low Cost Trading Tips - earlytimes.in
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics CFO & CBO Ryan Savitz Sells 20,000 Shares - TradingView
CFO Savitz Sells 20,000 ($903.6K) Of Dianthus Therapeutics Inc [DNTH] - TradingView
Ashland, Bitdeer, and More Stocks See Action From Activist Investors - Barron's
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighHere's Why - MarketBeat
Nothing is Better Than Dianthus Therapeutics Inc (DNTH) stock at the moment - setenews.com
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 45.0 USD By Investing.com - Investing.com Nigeria
Can Dianthus Therapeutics Inc. (87E) stock sustain breakout momentum2025 AllTime Highs & Detailed Earnings Play Alerts - Newser
CFO Savitz Files To Sell 20,000 Of Dianthus Therapeutics Inc [DNTH] - TradingView
Is Dianthus Therapeutics Inc. (87E) stock a contrarian opportunityWeekly Loss Report & Real-Time Volume Analysis - Newser
Dianthus Therapeutics stock hits 52-week high at 45.0 USD - Investing.com
Can Dianthus Therapeutics Inc. (87E) stock deliver double digit returnsPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat
CapEx per share of Dianthus Therapeutics, Inc. – TRADEGATE:87E - TradingView
Dianthus Therapeutics (DNTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
DNTH: Advancing two autoimmune therapies with strong clinical data and $525M cash runway - TradingView
Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stocks of Dianthus Therapeutics Inc (DNTH) are poised to climb above their peers - Setenews
Fed fueled market rally dnth breakout setup and ethereums critical test zone ahead | Fundamental analysis - RichTv
Avidity Partners Management LP Reduces Stake in Dianthus Therape - GuruFocus
What analysts say about Dianthus Therapeutics Inc stockStock Buy Signals & Top Analyst Picks Available for Free - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 43.69 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan
The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
How forex fluctuations impact Dianthus Therapeutics Inc. (87E) stockPortfolio Gains Summary & Safe Capital Growth Trade Ideas - newser.com
Why Dianthus Therapeutics Inc. stock remains resilient2025 Short Interest & Real-Time Volume Triggers - newser.com
How Dianthus Therapeutics Inc. (87E) stock performs in easing cyclesCEO Change & Daily Entry Point Alerts - newser.com
How Dianthus Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Views of Wall Street’s Leading Experts on Dianthus Therapeutics Inc - Setenews
Dianthus Therapeutics (DNTH): Reviewing Valuation Following Widening Losses in Latest Earnings Results - Sahm
Smart tools for monitoring Dianthus Therapeutics Inc.’s price action2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
What analysts say about Dianthus Therapeutics Inc 87E stock - earlytimes.in
How to escape a deep drawdown in Dianthus Therapeutics Inc.Earnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):